A statement from the
Both vaccines are approved and are part of
There is evidence from around the world that mixing vaccines can produce a greater immune response. In addition, schedules where the second dose is not necessarily the same as the first allows for more flexibility in the event of vaccine shortages.
According to the deputy director of IVI, Doctor
She added, "amid an ongoing global pandemic with inequitable and interrupted access to vaccines, it is vital to make available a good, or potentially even better, alternative to the homologous dose schedules we have relied on so far".
The Phase II trial is an observer-blind and randomised study. A total of 360 participants will be enrolled in the study with follow-ups until 48 weeks after the second vaccination. It is funded by the
Since it was launched in 2017, CEPI has focussed on developing vaccines against the Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and Chikungunya virus and has over twenty vaccine candidates against these pathogens in development. The organisation is a partnership between public, private, philanthropic, and civil organisations.
IVI is a non-profit intergovernmental organisation established in 1997 through an initiative launched by the
The INS is the national public health and research institute in
Copyright Agencia de Informacao de Mocambique. Distributed by AllAfrica Global Media (allAfrica.com)., source